{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.36","value":"-4.11"},{"groupId":"OG001","spread":"3.81","value":"-3.51"}]}],"title":"ICTP (n= 44, 42)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.79","value":"20.15"},{"groupId":"OG001","spread":"5.57","value":"14.59"}]}],"title":"Osteocalcin (44, 42)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.08","value":"-0.48"},{"groupId":"OG001","spread":"4.80","value":"-2.11"}]}],"title":"BAP (42, 40)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"Bone markers (carboxyterminal telopeptide of type I collagen (ICTP), osteocalcin (Oc) and bone-specific alkaline phosphatase (BAP) was measured on serum samples.","dispersionType":"Standard Deviation","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"MEAN","populationDescription":"FAS was used for analysis. \"N\" (number of subjects analyzed) signifies the subjects evaluable this measure and n=number pf participants analysed for this outcome measure at specific time point. Missing data was imputed by last observation carried forward (LOCF) method.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Change From Baseline in Biochemical Bone Markers:Carboxyterminal Telopeptide of Type I Collagen (ICTP), Osteocalcin, Bone-specific Alkaline Phosphatase (BAP)","type":"SECONDARY","unitOfMeasure":"Microgram per liter"}